Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Thom

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Proteomics. Clinical Applications|March 20, 2015
Urinary proteomic biomarkers to predict cardiovascular eventsCatriona E Brown, Nina S McCarthy, Alun D Hughes, et al.
Open Heart|February 4, 2025
Tissue Doppler echocardiography predicts long-term cardiovascular mortality: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) legacy 20-year follow-up studyAnenta Ratneswaren, Tong Wu, Amit Kaura, et al.
Hypertension (Dallas, Tex. : 1979)|October 26, 2018
Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood PressureNeil R Poulter, Christos Savopoulos, Aisha Anjum, et al.
JAMA Cardiology|July 28, 2020
Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH TrialNelson Wang, Abdul Salam, Ruth Webster, et al.
Plos One|June 8, 2011
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk, Anthony Rodgers, Anushka Patel, et al.
Atherosclerosis|August 17, 2010
Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individualsReecha Sofat, Juan P Casas, Meena Kumari, et al.
European Journal of Preventive Cardiology|March 6, 2016
Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular diseaseVanessa Selak, Chris Bullen, Sandrine Stepien, et al.
JAMA Cardiology|April 13, 2022
Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical TrialSonali R Gnanenthiran, Nelson Wang, Gian Luca Di Tanna, et al.
Atherosclerosis|December 20, 2017
Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A<sub>2</sub> formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Nina S McCarthy, Ciara Vangjeli, Praveen Surendran, et al.
Hypertension (Dallas, Tex. : 1979)|June 7, 2017
Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAlexander Bennett, Clara K Chow, Michael Chou, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Proteomics. Clinical Applications|March 20, 2015
Urinary proteomic biomarkers to predict cardiovascular eventsCatriona E Brown, Nina S McCarthy, Alun D Hughes, et al.
Open Heart|February 4, 2025
Tissue Doppler echocardiography predicts long-term cardiovascular mortality: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) legacy 20-year follow-up studyAnenta Ratneswaren, Tong Wu, Amit Kaura, et al.
Hypertension (Dallas, Tex. : 1979)|October 26, 2018
Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood PressureNeil R Poulter, Christos Savopoulos, Aisha Anjum, et al.
JAMA Cardiology|July 28, 2020
Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH TrialNelson Wang, Abdul Salam, Ruth Webster, et al.
Plos One|June 8, 2011
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk, Anthony Rodgers, Anushka Patel, et al.
Atherosclerosis|August 17, 2010
Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individualsReecha Sofat, Juan P Casas, Meena Kumari, et al.
European Journal of Preventive Cardiology|March 6, 2016
Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular diseaseVanessa Selak, Chris Bullen, Sandrine Stepien, et al.
JAMA Cardiology|April 13, 2022
Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical TrialSonali R Gnanenthiran, Nelson Wang, Gian Luca Di Tanna, et al.
Atherosclerosis|December 20, 2017
Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A<sub>2</sub> formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Nina S McCarthy, Ciara Vangjeli, Praveen Surendran, et al.
Hypertension (Dallas, Tex. : 1979)|June 7, 2017
Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAlexander Bennett, Clara K Chow, Michael Chou, et al.
Pageof 6